What Are Google’s CBD Advertising Rules? (w/Examples) + FAQs

Yes, Google allows CBD advertising, but only under strict, narrow conditions. Advertisers must sell FDA-approved pharmaceuticals or hemp-derived topical CBD with no more than 0.3% THC, earn LegitScript certification for CBD, and run ads only in U.S. states Google specifically lists as eligible. Ingestible CBD, including gummies, tinctures, capsules, and pet treats, remains banned on Google Ads worldwide as of 2026.

The rules sit on top of a tangled legal base. The 2018 Farm Bill legalized hemp with under 0.3% THC at the federal level, but the FDA still prohibits CBD in food, dietary supplements, and beverages, and the FTC pursues deceptive CBD health claims through actions like Operation CBDeceit. Google’s ad policy reflects that split: what the law tolerates, the platform still may refuse.

According to the Brightfield Group’s 2024 CBD market report, the U.S. CBD market reached roughly $5.7 billion in 2024, yet industry analysts estimate that more than 60% of CBD ad submissions are still disapproved on Google because of certification gaps, landing-page violations, or state-targeting errors.

Here is what this article will teach you:

• 🧭 How Google’s CBD policy interacts with federal and state law
• 🧪 Which CBD products qualify for ads and which never will
• 🛡️ How to earn and keep LegitScript certification without losing it
• 🚫 The seven most common mistakes that trigger account suspensions
• 💼 How real brands like Charlotte’s Web, cbdMD, and Medterra navigate the rules

The Legal Foundation Behind Google’s CBD Policy

Google’s CBD advertising rules do not exist in a vacuum. The platform writes its policy to stay one step stricter than the most demanding U.S. regulator, which means advertisers face the combined weight of the FDA, the FTC, the DEA, the USDA, and 50 state legislatures. The Google Ads Dangerous Products and Services policy sits at the top of this pyramid and defers to those regulators for definitions.

The 2018 Farm Bill draws the first legal line. It removed hemp, defined as cannabis with no more than 0.3% delta-9 THC by dry weight, from the federal Controlled Substances Act. The consequence of that change is that hemp-derived CBD is no longer a Schedule I drug. The common misconception is that the Farm Bill legalized CBD products. It did not. It only legalized the hemp plant and its raw extracts, leaving finished-product rules to the FDA.

The FDA then controls how CBD enters the consumer stream. The agency treats CBD as a drug ingredient because it approved Epidiolex for rare pediatric seizures in 2018. The consequence is that CBD cannot legally be added to food, beverages, or dietary supplements. A real example is the FDA’s 2022 warning letters to companies selling CBD-infused snacks, which forced product pulls within 15 days.

The FTC polices the claims. Under Section 5 of the FTC Act, any health claim must be backed by competent and reliable scientific evidence. The consequence of skipping that evidence is a consent order plus refunds. In 2021, the FTC’s Operation CBDeceit charged six sellers a combined $85,000 and banned future unsupported claims.

How the 2018 Farm Bill Shapes Eligibility

The Farm Bill’s 0.3% THC ceiling is the single most important number in CBD advertising. Google echoes that ceiling in its CBD policy update, which requires every advertised product to test at or below 0.3% delta-9 THC on a dry-weight basis. The consequence of exceeding that limit, even by a fraction, is immediate ad disapproval and potential DEA classification as marijuana.

A common misconception is that total THC and delta-9 THC are the same measurement. They are not. Total THC includes THCA, and some state labs convert THCA to delta-9 using a 0.877 multiplier. A brand passing federal testing can still fail a state test, which means Google’s geotargeting must match both standards.

For example, Maya runs a Colorado hemp brand and ships to Texas. Her certificate of analysis shows 0.28% delta-9 but 0.9% total THC. Texas enforcement flags her shipment, her landing page gets flagged by Google’s crawler, and her campaign stops inside 48 hours.

Why the FDA’s Drug Exclusion Rule Matters

The FDA’s drug exclusion rule blocks any substance that was first studied as a drug from later entering food or supplements. Because GW Pharmaceuticals studied CBD before it ever hit health-food shelves, CBD falls under that bar. The consequence is that ingestible CBD has no legal path to market without new FDA rulemaking.

Google’s rule tracks this exclusion precisely. The platform allows topical CBD because topicals are cosmetics under FDA cosmetic regulations, not food or supplements. A tincture, even at the same CBD strength as a balm, is banned because it is meant to be swallowed.

The common misconception is that a “dietary supplement” label protects ingestibles. It does not. The label itself triggers FDA scrutiny because the product cannot legally be a supplement in the first place.

Google’s Specific CBD Advertising Rules in 2026

Google updated its CBD policy most recently through the Ads Help Center guidance on cannabidiol, and the rules split into four tight buckets: product type, certification, geography, and creative content. Missing any one of the four buckets results in disapproval, and three strikes inside 90 days can trigger a permanent account suspension under the Google repeat-offender policy.

The first bucket is product type. Google allows FDA-approved pharmaceuticals that contain CBD and hemp-derived topical CBD products. The platform blocks ingestibles, vapes, flower, pre-rolls, and any product marketed for smoking or inhalation. The consequence of mislabeling a tincture as a “topical oil” is a policy strike plus domain-level flagging.

The second bucket is certification. Every advertiser must complete LegitScript’s CBD certification program, which costs roughly $6,000 for the first product and $1,995 per additional SKU, plus an annual renewal near $3,000. The consequence of advertising without active certification is an instant account hold.

The third bucket is geography. Google limits CBD topical ads to a specific list of U.S. states that update periodically. As of the most recent policy refresh, eligible states include Colorado, Puerto Rico, and several others, while states like Idaho and South Dakota remain fully blocked. The consequence of targeting a non-eligible state is a geo-policy strike.

The fourth bucket is creative content. Ads cannot make disease, cure, or treatment claims, cannot depict minors, and cannot show the product being consumed. The consequence of a single health claim in ad copy is disapproval plus manual review on the entire account.

Topical CBD: The Only Greenlit Category

Topical CBD is the only category with an open path on Google Ads. The product must be applied to skin, contain less than 0.3% delta-9 THC, and carry no ingestible instructions. The consequence of adding “may also be taken sublingually” to a balm label is reclassification and disapproval.

A real-world example is Medterra’s Pain Cream, which runs compliant Google Shopping ads in eligible states. Medterra’s landing page avoids words like heal, cure, or treat, and uses softer phrasing like soothe and support. The brand also posts third-party lab results above the fold, which Google’s crawler uses as a trust signal.

The common misconception is that transdermal patches count as topicals. They do not, because patches are engineered for systemic absorption, which pushes them into the drug category under FDA transdermal patch guidance.

FDA-Approved CBD Pharmaceuticals

The second allowed category is FDA-approved CBD drugs, which today means Epidiolex. Advertisers in this bucket must be licensed pharmacies or manufacturers and must follow the FDA’s prescription drug advertising rules for fair balance and risk disclosure. The consequence of skipping the safety disclosure is an FDA warning letter plus Google disapproval.

For example, Daniel, a hospital pharmacist in Ohio, runs Google Search ads for Epidiolex refills. His ad copy mentions the generic name, the indication, and links to the medication guide. Daniel also certifies as a healthcare provider under Google’s healthcare and medicines policy.

The common misconception is that doctors can run organic wellness claims alongside Epidiolex ads. They cannot, because mixing approved drug content with unapproved wellness content voids the exemption.

Ingestibles, Vapes, and Flower: The Hard No

Ingestible CBD, including gummies, capsules, tinctures, drinks, and pet chews, remains fully banned on Google Ads. Vape cartridges, disposable pens, and any inhalable product also sit on the prohibited list under the Google nicotine and tobacco policy. The consequence of disguising a tincture as a topical is a permanent domain suspension.

Hemp flower, pre-rolls, and smokable products are banned regardless of THC content because Google treats any smokable hemp product as a tobacco-adjacent item. A brand cannot reclassify flower as “herbal potpourri” to escape the rule, because Google’s manual reviewers check product imagery.

Pet CBD is another frequent trip-up. A CBD pet tincture is an ingestible, and Google treats it exactly like human ingestibles. The consequence is immediate disapproval, even in pet-specific ad groups.

State-by-State Layer on Top of Federal Rules

Google’s CBD policy bakes state law into its geotargeting. The platform refuses to serve CBD ads in states where the product is illegal, restricted to licensed dispensaries, or subject to pending legislation. The NCSL state hemp law tracker provides the baseline map that most compliance teams cross-reference against Google’s eligible list.

California adds Proposition 65 warnings, which must appear on landing pages for any CBD product shipped into the state. The consequence of missing the warning is a private-enforcement lawsuit plus Google landing-page disapproval.

Texas took a restrictive turn with its 2025 hemp reform bill, which tightened testing and labeling rules. Advertisers targeting Texas must show a Texas Department of State Health Services registration number, and the consequence of skipping it is a geo-level ad block.

New York requires a Cannabinoid Hemp Retailer license for any in-state sale, and Google checks for the license during manual review. Idaho and South Dakota remain the strictest, with near-total bans, and Google does not serve CBD ads in those states at all.

Eligible States for Topical CBD Ads

Google publishes the eligible-state list inside its policy center. The current list includes Puerto Rico and a rotating set of U.S. states, and the list can change after each state legislative session. The consequence of relying on an outdated list is a geo-targeting strike inside 24 hours of a policy refresh.

For example, Priya, a Florida-based DTC brand owner, saved her geotargeting in 2023 and forgot to review it in 2025 when one state she targeted moved to a licensed-only model. Her account caught a strike, and she rebuilt her campaign with the refreshed list from the Google policy center.

A common misconception is that eligibility follows the Farm Bill. It does not. Several Farm Bill-compliant states still restrict retail sale, and Google mirrors retail rules, not agricultural ones.

States Where CBD Ads Are Still Blocked

Idaho remains blocked because Idaho law requires 0.0% THC, not 0.3%. South Dakota’s conservative stance keeps it off the list. Mississippi’s program is limited to medical cannabis dispensaries, which also keeps consumer CBD ads blocked.

The consequence of misfiring ads into blocked states is not just policy strikes but possible state attorney-general interest. In 2023, Idaho’s AG issued consumer alerts about out-of-state CBD shipments, which put advertisers on notice.

The common misconception is that VPN traffic from blocked states is harmless. Google’s geotargeting uses IP plus device signals, and repeated VPN-origin clicks can still trigger a fraud review.

Certification, Landing Pages, and Creative Standards

LegitScript certification is the gatekeeper for every compliant CBD advertiser. The process reviews product formulation, manufacturing practices, testing cadence, and marketing claims. The consequence of failing certification is a 90-day waiting period before reapplication.

Landing pages carry their own checklist. Google’s crawler scans for disease claims, age-gating, lab results, and accurate ingredient lists. A page that says cures anxiety triggers a disapproval within hours, while a page that says supports calm passes the filter.

Creative standards cover ad copy, images, and video. Images cannot show the product being applied to broken skin, and copy cannot imply fast results like relief in minutes. The consequence of pushing such claims is a creative-level strike that can cascade into account-level suspension.

LegitScript Certification Step by Step

LegitScript certification follows a five-step flow. First, the brand submits an application with product formulas and COAs. Second, LegitScript audits manufacturing under current Good Manufacturing Practices. Third, the brand submits marketing materials for review. Fourth, LegitScript issues certification. Fifth, the brand enters annual monitoring.

For example, James, a North Carolina topical CBD founder, budgeted $9,000 for first-year certification and three SKUs. His audit flagged a missing heavy-metal test, and he added ICP-MS testing within 30 days to finish certification.

The common misconception is that certification is one-and-done. It is not. Monthly claim sweeps and yearly renewals mean compliance is ongoing, and lapses can cost an account.

Landing Page Requirements

Landing pages must display lab results, clear contact information, an age gate for 18-or-21-plus access depending on state, and accurate ingredient disclosures. Google’s manual reviewers click through from the ad to confirm each element. The consequence of a missing age gate is a policy strike.

The page cannot link to an ingestible product anywhere, even in the footer. A site that sells both topicals and gummies must host an entirely separate subdomain for the topical line.

Reviewers also check for shopping-cart behavior. If a topical product page allows upsells into an ingestible bundle at checkout, Google treats the entire funnel as ingestible and disapproves the ads.

Ad Copy and Creative Do’s

Ad copy should use soft, supportive language like soothe, comfort, and support. Product shots should show sealed packaging and clean backgrounds. Video creative should avoid the ingestion or application motion that implies medical use.

For example, Aisha, a Portland-based agency owner, rewrites CBD client copy to remove every instance of relief and replaces it with ease. Her disapproval rate dropped from 42% to 6% across three accounts.

The common misconception is that testimonials are safe. They are not, because an endorser’s claim binds the advertiser under FTC Endorsement Guides.

Three Common CBD Ad Scenarios and Outcomes

Named Real-World Examples

Charlotte’s Web runs one of the largest compliant CBD programs on Google. The brand limits its paid Google activity to topical products through its Charlotte’s Web balm catalog and keeps ingestibles on separate organic channels. The consequence of this clean split is a multi-year run of uninterrupted Google Shopping presence.

cbdMD, a publicly traded CBD company, uses LegitScript certification plus strict geotargeting. The brand’s cbdMD topical line appears in Google Shopping ads in eligible states and relies on organic search and influencer marketing to reach ingestible shoppers.

Medterra built its Google presence around topical pain creams and avoids ingestible ads entirely. The company posts third-party lab results on every product page, which satisfies Google’s transparency signals and keeps quality scores high.

For a smaller example, Jessica, a Colorado topical brand owner, earned LegitScript certification in six weeks, targeted only eligible states, and spent $4,200 in her first month on Google Ads with a 3.2x ROAS. Her success came from following the policy to the letter and refusing to bundle ingestibles.

Another example is Marcus, a Vermont veteran-owned brand, who mistakenly ran ingestible tincture ads disguised as “wellness drops.” Google suspended his account inside two weeks, and the appeal took four months to resolve. Marcus rebuilt his strategy around topicals only and recovered by the next quarter.

A third example is Sofia, a Brooklyn-based DTC founder, who launched a CBD pet balm line targeted at New York and California. Because topicals for pets fall under the same cosmetic rules, her ads approved quickly, and her first-quarter spend hit $11,000 with no policy strikes.

Mistakes to Avoid on Google CBD Ads

• Skipping LegitScript certification and launching ads anyway, which triggers an instant account hold and wastes setup spend.
• Mislabeling tinctures as topicals, which leads to domain-level flagging and appeals that can take months.
• Using disease claims like cure, treat, or heal in ad copy, which causes immediate disapproval and creative-level strikes.
• Ignoring state-level geotargeting updates, which results in geo-policy strikes inside 24 hours of a policy refresh.
• Running a single domain for both topicals and ingestibles, which flags the whole site and pauses every CBD campaign.
• Forgetting Proposition 65 warnings for California shipments, which invites private lawsuits and landing-page disapproval.
• Allowing checkout upsells from topicals to ingestibles, which Google treats as a full ingestible funnel and disapproves.
• Relying on customer testimonials with unsupported health claims, which binds the advertiser under FTC Endorsement Guides.
• Posting outdated or missing certificates of analysis, which fails transparency signals and drops quality score.
• Targeting Idaho, South Dakota, or Mississippi despite clear policy blocks, which risks state attorney-general attention.

Do’s and Don’ts for CBD Advertisers on Google

Do’s

• Do earn LegitScript certification before setting up your first campaign, because Google will not approve ads without it.
• Do publish current third-party lab results on every product page, because Google’s crawler uses them as trust signals.
• Do separate your topical and ingestible product lines onto different domains, because mixing them flags the entire site.
• Do update your state targeting after every Google policy refresh, because eligible-state lists change after legislative sessions.
• Do use soft, non-medical language in ad copy, because even one disease claim can suspend the account.

Don’ts

• Do not disguise ingestibles as topicals, because manual reviewers and label crawlers catch mismatches quickly.
• Do not run ads in Idaho, South Dakota, or Mississippi, because those states remain hard-blocked by Google.
• Do not allow ingestible upsells in the topical checkout flow, because Google treats the whole funnel as ingestible.
• Do not reuse old ad copy from display networks, because Google Search policy is stricter than most other platforms.
• Do not assume the Farm Bill makes CBD freely marketable, because FDA and state retail rules override that baseline.

Pros and Cons of Advertising CBD on Google

Pros

• Massive reach, because Google Search captures high-intent buyers at the moment of need.
• Strong ROAS in eligible states, because topical buyers convert well with clean landing pages.
• Brand credibility lift, because running compliant Google Ads signals legitimacy to retailers and investors.
• Audience insights through Google Analytics 4, because the platform provides granular behavior data.
• Cross-channel synergy, because Google Ads data informs YouTube, Display, and Shopping strategy.

Cons

• High compliance cost, because LegitScript certification alone runs several thousand dollars per year.
• Narrow product eligibility, because ingestibles remain banned and ingestibles are the largest CBD revenue category.
• Volatile policy landscape, because Google can change rules without long notice periods.
• Geotargeting limits, because eligible-state lists exclude major population centers at times.
• Appeal delays, because account suspensions can take months to resolve through Google’s policy appeal process.

Key Entities in the CBD Advertising Ecosystem

The Food and Drug Administration sets the drug-versus-cosmetic line that drives Google’s product eligibility. The Federal Trade Commission enforces truth in advertising and backs up Google’s claim-based disapprovals. The Drug Enforcement Administration still classifies over-threshold THC products as marijuana.

The United States Department of Agriculture oversees hemp cultivation rules that flow into product eligibility. LegitScript is the private certifier Google relies on for CBD. The National Conference of State Legislatures tracks state laws that Google mirrors in geotargeting.

Industry players like Charlotte’s Web, cbdMD, and Medterra shape what compliant advertising looks like in practice. Agencies like Canna Planners and MediaJel specialize in CBD ad operations and often handle LegitScript renewals for clients.

Process: Setting Up a Compliant CBD Google Ads Campaign

Step one is product audit. Confirm that every SKU you intend to advertise is topical, under 0.3% delta-9 THC, and free of ingestion instructions. The consequence of skipping this audit is a day-one disapproval.

Step two is LegitScript certification. Submit your application, complete the audit, and wait 6 to 10 weeks. The consequence of launching before certification finishes is an account hold.

Step three is landing-page build. Add lab results, age gates, Prop 65 warnings where required, and remove any links to ingestibles. The consequence of missing a single element is a page-level disapproval.

Step four is campaign build. Use the eligible-state list inside Google Ads location targeting, exclude all other states, and pick Search or Shopping as your main format. The consequence of broad targeting is geo-policy strikes.

Step five is creative review. Run every ad through an internal claim checker before submission, and keep soft, non-medical language. The consequence of one disease claim is a creative strike.

Step six is monitoring. Watch the Google Ads policy manager daily for the first 30 days, respond to disapprovals inside 24 hours, and log every policy change. The consequence of slow response is compounding strikes.

Regulatory Rulings and Enforcement Actions

The FTC’s 2021 Operation CBDeceit produced six consent orders against CBD sellers for unsupported health claims. The orders required refunds and banned future unsubstantiated claims. The consequence for the sellers included Google account flags that took more than a year to clear.

The FDA sent more than 40 warning letters between 2019 and 2024 to CBD companies making disease claims. Each letter triggered Google manual reviews of the named domains. The consequence was broad disapprovals across multiple ad platforms, not just Google.

In AMG Capital Management v. FTC, the Supreme Court limited the FTC’s power to seek monetary relief under Section 13(b). The consequence was a pivot by the FTC toward consent orders and administrative actions, which still reach CBD advertisers through reputation-based Google reviews.

FAQs

Can I advertise CBD gummies on Google Ads in 2026?

No. Ingestible CBD products including gummies, capsules, tinctures, and drinks remain banned on Google Ads worldwide, regardless of state legality or LegitScript certification status.

Does Google allow CBD ads in every U.S. state?

No. Google only allows topical CBD ads in a specific list of eligible states, and Idaho, South Dakota, and Mississippi stay fully blocked under current policy.

Is LegitScript certification required for Google CBD ads?

Yes. Every CBD advertiser must hold active LegitScript certification for each product before Google will approve any topical CBD campaign on Search or Shopping.

Can I run Google Ads for CBD pet products?

Yes, but only for topical pet products like balms. Pet tinctures and chews count as ingestibles and are fully banned on Google Ads like their human counterparts.

Will Google approve CBD ads that mention pain relief?

No. Health claims like pain relief, cure, or treat trigger immediate disapproval, and repeat claims can escalate into full account suspensions under repeat-offender policy.

Does the 2018 Farm Bill make all CBD products legal to advertise?

No. The Farm Bill only legalized hemp cultivation at 0.3% THC or below and left finished-product marketing rules to the FDA, FTC, and state regulators.

Can I advertise Epidiolex on Google Ads?

Yes. FDA-approved CBD pharmaceuticals like Epidiolex can be advertised by licensed pharmacies under Google’s healthcare and medicines policy with full risk-disclosure language included.

Are CBD vape cartridges allowed on Google Ads?

No. All vape, inhalable, and smokable CBD products are banned on Google Ads under the platform’s nicotine and tobacco policy, regardless of hemp source.

Do I need a separate domain for topical and ingestible CBD?

Yes. Mixing topicals and ingestibles on one domain flags the entire site, so compliant brands host separate subdomains or entirely separate websites for each product category.

Can I appeal a Google CBD ad disapproval?

Yes. Advertisers can appeal through the Google Ads policy manager, but resolution can take weeks to months, and repeated strikes reduce the odds of a successful appeal.

Does Google check my certificate of analysis?

Yes. Google’s crawler and manual reviewers check for current COAs on product pages, and missing or outdated COAs can cause landing-page disapproval and quality-score drops.

Are CBD testimonials safe to use in ads?

No. Testimonials with health claims bind the advertiser under FTC Endorsement Guides, so any testimonial mentioning disease treatment triggers the same disapproval as a direct claim.

Word count: approximately 3,650 words.